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 Prostate cancer is the second leading cause of all male cancer deaths. One of the 
factors present in malignant prostate cells and shown to support its metastatic growth is the 
neuropeptide neurotensin (NT). The primary goal of the present study was to establish the 
feasibility of using a newly developed paramagnetic receptor ligand for NT and non-
invasive ultrahigh-field magnetic resonance (MR) imaging to visualize prostate cancer in 
rodents. Orthotropic xenografts were initiated in six-week old male BALB/c nu/nu athymic 
mice (n = 28) by intra-prostatic (ventral lobe) inoculation of human prostate cancer cells 
(10µL of PC3 cells (106 /100l)). Palpable tumors developed within 30-60 days. A micro-
imager utilized in these studies was an actively shielded 9.4T, 89 mm bore, Oxford 
superconducting magnet with a 100 gauss/cm gradient system. Prior to contrast injection, 
T2 weighted anatomy scans were done to localize the tumor with a spin-echo multi-slice 
sequence with TR: 2000 TE: 40 and NEX: 1 in both coronal and axial planes. The 
paramagnetic ligand data sets were collected with a spin-echo, T1 weighted pulse sequence 
(MSME): TR 300 msec; TE 5 msec; NEX 4 in both axial and coronal planes. The data sets 
were taken initially at 5-min intervals post contrast injection for the first half hour and then 
at 15 min intervals for the next 1.5-2 hours for a time series analyses. The temporal 
distribution of MR signal intensity in various regions were determined in the absence and 
presence of NT. Our results confirm that the novel NT molecule was protected from 
enzymatic degradation and capable of forming a high affinity paramagnetic NT ligand with 
an extended half-life. During the imaging studies, the signal intensity increased by 200 % in 
the region of the tumor. This increase in signal intensity approached maximum binding 
within 30 minutes and remained visible for 1 hour post-injection of the contrast agent.  
Taken together, these findings suggest that it is feasible to detect and image prostate cancer 
using a paramagnetic NT ligand and the emergence of the NT receptor ligand that may be 
used as a diagnostic marker for prostate cancer in humans. 
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INTRODUCTION 
 
 Prostate Cancer is the second leading cause of death from cancer and is the most common 
malignancy in north-American men, with 1 in every 5 patients developing invasive cancer. It 
accounts for an estimated 29% of all new cancer cases diagnosed in U.S. men (1). Although the 
current diagnostic processes for the prostate cancer (including the digital rectal examination, 
measurement of prostate-specific antigen, transrectal ultrasonography and biopsy) may have 
increased (2) the number of men being screened, the mortality rate for this disease has not 
subsided. To minimize mortality, emerging methods of localized tumor therapy (aimed at 
replacing surgery and radiation) are being considered particularly establishing the requirement for 
accurate, concise 3D localization of prostate tumors.  
 Neurotensin (NT) is a 13 amino-acid peptide found in the central and peripheral nervous 
systems and endocrine cells of several tissues (3, 4). Recent evidence shows NT can promote the 
development and growth of certain tumors, particularly pancreatic (5, 6), lung (7), colon (8) and 
prostate cancers (9, 10). Blocking the NT receptor with the highly selective antagonist, SR48698 
inhibits the tropic effects of NT on xenografted human colon (8, 11) and prostate cancer (9) cells 
(PC3). The presence of NT receptors in tumor correlates with the emergences of cancerous 
growth. These findings suggest that the emergence of NT receptor may be a diagnostic marker for 
prostate cancer. Considering the strong association of NT with prostate cancer, we have 
developed a paramagnetic ligand that recognizes the NT receptor.  
 With the advent of animal MR spectrometers of ultrahigh-field strengths like 9.4 Tesla 
(T) that enables to study biological structures of 50µm or less and technical developments in MRI 
combined with the use of selective contrast agent can potentially improve early detection, 
diagnosis and 3D localization of prostate tumor (12, 13, 14). This manuscript explores the 
viability of using the newly developed ligand (as a contrast agent) and MR Imaging to 
demonstrate the presence and extent of prostate cancer. The key to visualizing NT binding sites is 
the internalization of the receptor-ligand complex and the concentration of the paramagnetic 
atoms inside the cells. The presence of paramagnetic NT receptor ligand shortens T1 relaxation, 
thus creating a contrast in the MR Image (due to difference in T1 relaxation rates), from 
surrounding tissues.  
 MRI using gadolinium (GD) enhancement is becoming a common technique in the study 
of prostate cancer (15, 16). When gadolinium is combined with NT (Gd-NT), our results show 
that the paramagnetic ligand complex binds to the NT receptors in the tumor xenografted into the 
prostate of nude mice. MR Images showed enhanced signal intensity in the areas of the tumor as 
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compared to the surrounding tissue. The use of antagonist (SR48692) illustrates that the receptor-
ligand interaction exhibited saturablity (the antagonist blocks NT receptors in a dose dependent 
manner) (8). Our experiments also demonstrate that the newly developed Gd-NT complex shows 
tumor specificity, sensitivity with an enhanced half-life. 
 
 
MATERIALS AND METHODS 
 
Animals 
 These studies used six-week old male balb/c nu/nu athymic mice (nude mice) obtained 
from Charles Ricer Breeding Laboratory (Wilmington, MA). The mice were housed under aseptic 
conditions (enclosed overheated laminar hood, sterilized cages, bedding and water) and 
maintained at ambient temperature (22-24º C) in a light controlled (14 h/day) room. All animals 
were maintained in an accredited facility at University of Massachusetts Medical School. Food 
and water was provided ad libitum. All animals were acquired and cared for in accordance with 
the guidelines published in NIH Guide for Care and Use of Laboratory Animals (National 
Institutes of Health Publications N. 80-23, Revised 1996).  
 
Surgical Orthotropic Implantation 
 PC3 cells are known to be one of the most aggressive prostate cancer cell lines, 
which is easily xnografted into nude mice (17). Right before implantation, PC-3 cells 
(obtained form ATCC) were trypsinized and re-suspended in DMEM with 10% FCS. Xenografts 
were initiated in the mice (n=28) by intra-prostatic injection. Brief surgical procedures for 
transplantation of tumors were performed under aseptic conditions and the animals were 
anesthetized with isoflurane (1.5%). 20 µL of PC3 cells (2x106/ 200 µL) were then injected into 
the ventral lobe of prostate, using Hamilton syringe with a 30 gauge needle (18, 19). The 
abdominal incisions were then sutured (with discontinuous, absorbable suture) using 6.0 nylon 
thread and the animals were then transferred to a recovery cage. Post surgical observations 
including the assessment of animals for signs of infection were carried out daily for next 14 days. 
  
MRI Study 
The micro imager utilized in these studies is an actively shielded 9.4 T, 89 mm bore, 
Oxford superconducting magnet with a 100 gauss/cm gradient system (Resonance Research Inc.). 
Mice were implanted with tail vein for delivery of contrast agent prior to imaging study. Prior to 
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contrast injection, T2 weighted anatomy scans were obtained to localize the tumor, with a spin-
eco multi-slice sequence with TR: 2000 ms TE: 40 ms and NEX: 1 in both coronal and axial 
planes. 
 Once the tumor is localized on the MR Image the paramagnetic ligand (Gd-NT) was then 
injected in the mice (through the tail vein 1 ml/s). Post Gd-NT (0.1 mmol) administration data 
sets were collected with a multi-slice (30 slices per plane) spin-echo, T1 weighted pulse 
sequence: TR 300 ms; TE 5 ms; NEX 4 in both axial and coronal planes. The data sets initially 
were taken at a 5-min interval, for first 30-min, immediately post contrast injection and then-after 
at a 15-min interval for the next 1.5-2 hours for a time series analyses. The temporal distribution 
of MR signal intensity in various regions was determined in absence and presence of Gd-NT. 
Specific binding activity expressed as percent change in MR signal intensity/unit area over time. 
Specific binding were estimated as the difference in MR signal intensity for a given region of the 
tumor in the absence and presence of NT receptor ligand. Respiratory motion during scan was 
minimized with an abdominal belt. Care was taken during data analysis to correct for any 
abdominal/peristaltic movement in the 2-3 hours of scanning. In our anatomical scans tumors 
areas were identified as the areas with increase signal intensity on T2-weighted images and 
change in signal intensity, post Gd-NT administration, was followed on the T1- weighted images.  
Experiments using SR48968 (antagonist) were carried out to test the saturablity of the 
Gd-NT ligand. Four different doses (5, 4, 3 and 1mmol) of SR48968 were administered 
intravenously, just prior to Gd-NT administration, but the later part of the experimental 
procedures was kept exactly the same as the one used for the Gd-NT ligand. 
 
Autopsy and histology 
At the end of experiments (4-6 weeks after the tumor cells inoculation), mice were 
sacrificed by CO2 asphyxiation.  Careful gross examination of the primary and secondary growth 
of prostate tumor was performed at autopsy. The primary tumor of the prostate, various prostatic 
lobes, seminal vesicles, urinary bladder and the urethra were excised from the mice.  Regional 
and distant lymph nodes, lungs, liver, spleen, lower abdominal wall (organs where metastasis 
could occur) were subjected to the evaluation of metastasis. All tissues collected were fixed in 
10% neutral buffered formal saline, routinely embedded, sectioned and stained with hematoxylin 
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 RESULT: 
 
Establishment of orthotopic xenografts of human prostate cancer cells  
 From our previous studies on NT PC3 cells growth in vivo ectopic tumors were visible to 
eye by Day 15 post xenograft and significant difference in NT binding were recognized by Day 
16 post xenograft. However, when the PC3 cells were implanted into the ventral prostate 
(orthotropic) the tumor growth was less aggressive and significantly different form that observed 
with ectopic tumor. In order to see the earliest formation of tumor, imaging began 72 hrs after the 
PC3 cells were xenografted into the nude mouse. The pilot studies demonstrated that inoculation 
with PC3 cells were not clearly visible with MRI until the end of the first week and were palpable 
30-60 days post inoculation. Several regions of interests (ROIs) including the tumor –PC3 
implanted region, bladder and the healthy prostate gland were identified and followed. 
The growth of inoculated human PC3 cells in murine ventral prostate gland resulted in 
gross and palpable tumors accompanied by local invasion into the adjacent lateral and dorsal 
lobes of prostate. The regular glandular architecture of the involved prostate lobes was dislodged 
by the overwhelming growth of human prostate cancer cells (Fig 2[2]). In some (three) mice, 
tumor-infiltrated lymph nodes and lower abdominal wall were observed adjacent to the primary 
tumor. During the course of our study (90 days) no distant metastases were detected in visceral 
organs (liver, kidney, lung and spleen) and distant lymph nodes by gross and microscopic 
examinations. Fig 2[3] demonstrated the histological details of the poorly differentiated 
phenotypes of PC3 xenografts in the murine prostate gland. 
 
MRI and Contrast Agent 
A mouse, 45 days post inoculation, was used to acquire the MR images shown in Fig. 1 
A, B & C. Once the control MR images (T1 and T2 weighted images in coronal and axial plane) 
were acquired, 0.1mmol Gd-NT contrast agent was administered intravenously and post-contrast 
T1 weighted (coronal and axial) images were acquired every 5-min for first 30-min and at an 
interval of 15-min there after for 90-min. As shown in Fig. 1 D signal intensity enhances in the 
inoculated lobe of the prostate as compared to non-inoculated lobe suggesting that the ligand is 
site specific. Maximum binding is acquired in about 15-30 minutes and the contrast lasts for 
about 90 minutes post injection. In contrast the regular tissue (without tumor) dose not shows any 
signal intensity enhancement (Fig. 1 D). 
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MRI and Histo-Patalogy 
 The MRI data acquired were corroborated with histological analysis. The histopathologic 
images confirmed the size and localization of the tumor as obtained from the MRI studies. Three 
axial T2 weighted (TR=2000ms, TE=40ms, NEX=1) MR Images were aligned with its 
corresponding histopathologic images (Fig.2 (1) & (2)). The tumor in this case grew up to 1cm in 
diameter (6 weeks post inoculation), which was confirmed by both MRI and histolopathologic 
results. It is very easy to see the tubules and the tumor cells in the high resolution histopathologic 
image (Fig. 2 (3) A).      
 
Sight Specificity 
The MR Images collected Pre (Fig. 3 C) and 5 minutes Post (Fig. 3 D) Gd-NT 
administration shows that the contrast enhancement is site specific, tumor regions, and can be 
easily visualized. These images are spatially corroborated with histopathologic (Fig. 3 A) and T2 
weighted MR image (Fig. 3 B) of the tumor region. We also found that the contrast started to 
develop in the bladder; this was very consistent in all of our studies. This suggests that 
paramagnetic ligand is site specific and has superior half life, as the contrast form all the other 
organ (tissues) is washed out very quickly (within 5 min)  except the tumor region where the 
ligand is bound with the NT receptor and stays in there for as long as 90-min. 
 
Longitivity & Saturablity 
 A comparative study between receptor-ligand complex and antagonist (SR48698) shows 
that the NT receptor ligand exhibits saturablity, as seen in Fig. 4. The plot of % contrast change 
against time shows that there is no signal intensity enhancement in the antagonist case, where as 





 Our Studies indicate that the key to visualizing NT binding sites is the internalization of 
the receptor-ligand complex and the concentration of the paramagnetic atoms inside the cells. The 
presence of paramagnetic NT receptor ligand shortens T1 relaxation, thus creating a contrast in 
the MR Image (due to difference in T1 relaxation rates), from surrounding tissues.  
 However, couple of issues arose when we initiated the inoculation procedure including 
the viability of the cells in vivo, the volume of inoculants, and the placement of the cells. Initially 
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we tried to inoculate PC3 cells S.C into the right flank of mice midway between the arm and the 
leg. After many attempts, we arrived at our final protocol which decreased the volume to 20µL 
(lower then we initially attempted) and introduced the cells directly into the ventral lobe of the 
prostate. It appears that limiting the volume of cells decreased cell loss to the surrounding tissue. 
Although the isotropic model was appreciably more difficult to attain, it was undoubtedly more 
akin to the human model (18, 20, 21). These modifications currently produce much higher rate of 
successful tumor growth (65-70 %). The tumor grew anywhere form 1.0-1.5 cm in size after 
about 30-60 days post inoculation. 
 Although these large tumors where easily visible, it was not easy to trace small tumors 
using the T2 weighted images (22, 23). Use of selective contrast agent proved to be a very precise 
method in tracking such small tumor. The SNR (signal to noise ratio) also greatly improved with 
the use of contrast agent. The specificity of the paramagnetic ligand, unlike T2 weighted 
technique, increases the signal intensity in the tumor region and the tumor region only. At its peak 
the signal intensity increased to 200% of the signal intensity before Gd-NT administration, and 
stayed within the tumor region for as long as 30-min, making the estimation and detection process 
convenient and highly precise. 
Pre-saturation of NT receptor with 4 different dose of antagonist SR48692 changed the 
MR signal intensity and there by demonstrating the dose dependent nature of the receptor-ligand 
saturablity.  
MRI using gadolinium (GD) enhancement is becoming a common technique in the study 
of prostate cancer (15, 16). When gadolinium is combined with NT (Gd-NT), our results show 
that the paramagnetic ligand complex binds to the NT receptors in the tumor xenografted into the 
prostate of nude mice. MR Images showed enhanced signal intensity in the areas of the tumor as 
compared to the surrounding tissue. The use of antagonist (SR48692) illustrates that the receptor-
ligand interaction exhibited saturablity (the antagonist blocks NT receptors in a dose dependent 
manner) (8). Our experiments also demonstrate that the newly developed Gd-NT complex shows 
tumor specificity, sensitivity with an enhanced half-life. 
In summary, we have shown that the MR images exhibited high contrast enhancement of 
tumor region and tumor region only, post Gd-NT ligand administration. This study supports the 
use of Gd-NT ligand in conjunction with non-invasive Magnetic Resonance Imaging as a useful 
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Figure. 1. T1 (TR=300ms, TE=5ms, NEX=4) weighted MRI of prostate region showing a 
developed tumor and the contrast with the tumor (A and B; pre- and 15 minute post-contrast MR 
images. Prostate gland outlined.). A % contrast change (% of control) timeline (D) shows that the 
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Figure. 2. Three T2 weighted MR Images (1: A, B & C) of prostate tumor region are aligned with 
corresponding histopathologic slides (2: A, B & C). A high resolution histopathologic image 
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Figure. 3. Histopathologic image (A) of prostate tumor is aligned with its corresponding T2 
weighted MR Image (B). Corresponding pre (C) and 5 minutes post-contrast (D) T1 weighted 
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Figure. 4. Axial T1 weighted (TR=300ms, TE=5ms, NEX=4), 10 minutes post-contrast, MR 
images are acquired for two cases; Gd-NT contrast agent and antagonist (A and B). Mean % 
contrast change and standard deviation (SD) is compared (C) for both the cases and it can be seen 
that the contrast stays in the tumor for about 60 min in the case of Gd-NT contrast administration. 
Error bars indicate SD from the mean. 
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